Aclaris Therapeutics (ACRS) Stock: Buy, Sell, or Hold?
ACRS - Aclaris Therapeutics, Inc.
$4.41
-0.85 (-16.16%)
▼
5d:
-18.03%
30d:
-26.74%
90d:
-20.68%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ACRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ACRS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ACRS is currently trading at $4.41, which is considered oversold relative to its 30-day fair value range of $5.22 to $6.12.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is currently testing key support at $4.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 16.2% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.18 (+130.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is currently testing key support at $4.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 16.2% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.18 (+130.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.22 -
$6.12
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-16.2%)
- BULLISH: Trading 130.9% below Wall St target ($10.18)
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
- CAUTION: 5-day price weakness (-18.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$5.22 -
$6.12
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.35
Resistance Level
$5.77
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.60
Wall Street Target
$10.18
(+130.9%)
Revenue Growth (YoY)
-8.3%
Share & Embed Analysis
Last updated: October 02, 2026 12:04 AM ET
Data refreshes hourly during market hours. Next update: 1:04 AM
Data refreshes hourly during market hours. Next update: 1:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 55 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
